Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html?taid=6abfcb18a7b7100001e74cf8&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter